Market News

Analysts See $0.08 EPS for Student Transportation Inc. (STB); Conatus Pharmaceuticals (CNAT) Has 1.1 Sentiment

Student Transportation Inc. (NASDAQ:STB) Logo

Conatus Pharmaceuticals Inc (CNAT) investors sentiment decreased to 1.1 in 2017 Q4. It’s down -0.73, from 1.83 in 2017Q3. The ratio worsened, as 34 active investment managers started new or increased positions, while 31 trimmed and sold equity positions in Conatus Pharmaceuticals Inc. The active investment managers in our database now own: 11.71 million shares, up from 10.89 million shares in 2017Q3. Also, the number of active investment managers holding Conatus Pharmaceuticals Inc in top ten positions was flat from 1 to 1 for the same number . Sold All: 14 Reduced: 17 Increased: 23 New Position: 11.

Analysts expect Student Transportation Inc. (NASDAQ:STB) to report $0.08 EPS on May, 9.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.08 EPS. STB’s profit would be $7.31M giving it 23.39 P/E if the $0.08 EPS is correct. After having $0.09 EPS previously, Student Transportation Inc.’s analysts see -11.11% EPS growth. The stock increased 0.07% or $0.005 during the last trading session, reaching $7.485. About 218,713 shares traded. Student Transportation Inc. (NASDAQ:STB) has risen 29.21% since April 17, 2017 and is uptrending. It has outperformed by 17.66% the S&P500.

Conatus Pharmaceuticals Inc., a biotechnology company, focuses on the development and commercialization of novel medicines to treat liver diseases in the United States. The company has market cap of $112.42 million. The Company’s product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for patients with portal hypertension; for liver function; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response. It currently has negative earnings.

Ratings analysis reveals 100% of Conatus Pharma’s analysts are positive. Out of 2 Wall Street analysts rating Conatus Pharma, 2 give it “Buy”, 0 “Sell” rating, while 0 recommend “Hold”. The lowest target is $5.0 while the high is $18.0. The stock’s average target of $11.50 is 207.49% above today’s ($3.74) share price. CNAT was included in 2 notes of analysts from November 9, 2016. Stifel Nicolaus maintained the stock with “Buy” rating in Wednesday, November 9 report. The stock of Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) earned “Buy” rating by H.C. Wainwright on Tuesday, December 20.

Analysts await Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) to report earnings on May, 3. They expect $-0.17 EPS, down 21.43% or $0.03 from last year’s $-0.14 per share. After $-0.15 actual EPS reported by Conatus Pharmaceuticals Inc. for the previous quarter, Wall Street now forecasts 13.33% negative EPS growth.

Mpm Asset Management Llc holds 3.89% of its portfolio in Conatus Pharmaceuticals Inc. for 2.10 million shares. Courage Capital Management Llc owns 200,000 shares or 0.66% of their US portfolio. Moreover, Acadian Asset Management Llc has 0.02% invested in the company for 815,628 shares. The France-based Axa has invested 0.01% in the stock. Bridgeway Capital Management Inc, a Texas-based fund reported 136,300 shares.

The stock increased 0.81% or $0.03 during the last trading session, reaching $3.74. About 435,315 shares traded. Conatus Pharmaceuticals Inc. (CNAT) has risen 12.92% since April 17, 2017 and is uptrending. It has outperformed by 1.37% the S&P500.

Student Transportation Inc., together with its subsidiaries, provides school bus transportation and management services to public and private schools in North America. The company has market cap of $684.26 million. The firm offers contracted, managed, special needs transportation, direct-to-parent, and charter services. It has a 26.26 P/E ratio. It operates approximately 290 contracts with a fleet of 13,000 vehicles.

Investors sentiment decreased to 1 in Q4 2017. Its down 1.16, from 2.16 in 2017Q3. It dived, as 11 investors sold Student Transportation Inc. shares while 19 reduced holdings. 7 funds opened positions while 23 raised stakes. 26.04 million shares or 7.62% more from 24.20 million shares in 2017Q3 were reported. Toronto Dominion Bank & Trust owns 19,901 shares. Savings Bank Of Nova Scotia stated it has 48,204 shares. Raymond James Financial Advsrs invested in 0% or 22,301 shares. Credit Suisse Ag accumulated 55,536 shares. Oppenheimer Communication reported 51,327 shares. Wells Fargo & Mn reported 9,101 shares. Ejf Capital Ltd reported 50,000 shares stake. Ubs Asset Americas holds 0% of its portfolio in Student Transportation Inc. (NASDAQ:STB) for 69,780 shares. Commercial Bank Of Montreal Can holds 44,491 shares or 0% of its portfolio. 12,016 were reported by Dynamic Solutions Ltd Com. Security Natl has 0% invested in Student Transportation Inc. (NASDAQ:STB) for 2,000 shares. Great West Life Assurance Can reported 4,708 shares stake. 1.24 million were accumulated by Morgan Stanley. Deroy & Devereaux Private Counsel Inc invested in 355,600 shares. Bankshares Of America De, North Carolina-based fund reported 52,352 shares.

Among 7 analysts covering Student Transportation (NASDAQ:STB), 2 have Buy rating, 1 Sell and 4 Hold. Therefore 29% are positive. Student Transportation had 11 analyst reports since August 10, 2015 according to SRatingsIntel. The firm has “Buy” rating by Stifel Nicolaus given on Friday, September 22. Stifel Nicolaus maintained Student Transportation Inc. (NASDAQ:STB) on Monday, July 17 with “Buy” rating. The stock of Student Transportation Inc. (NASDAQ:STB) earned “Market Perform” rating by BMO Capital Markets on Friday, September 22. The stock of Student Transportation Inc. (NASDAQ:STB) has “Sector Perform” rating given on Thursday, September 17 by Scotia Capital. The stock has “Market Perform” rating by Raymond James on Wednesday, February 28. The rating was maintained by Stifel Nicolaus with “Buy” on Monday, September 11. The stock has “Market Perform” rating by BMO Capital Markets on Monday, August 10. The rating was downgraded by Barrington Research to “Underperform” on Wednesday, February 28. The stock has “Sector Perform” rating by National Bank Canada on Friday, June 2. The firm has “Outperform” rating by Raymond James given on Friday, December 2.

Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) Institutional Positions Chart

Leave a Reply

Your email address will not be published. Required fields are marked *